Business ❯ Pharmaceutical Industry

Drug Manufacturers

Pricing Strategies Novo Nordisk Pfizer Eli Lilly Market Dynamics Kenvue Novo Nordisk and Eli Lilly Pricing Agreements Price Negotiation AstraZeneca Merck Market Impact Market Competition Eli Lilly and Novo Nordisk Negotiation Strategies Amgen Market Regulations Price Negotiations Profit Margins Purdue Pharma Medication Pricing Medicare Part D Boehringer Ingelheim GLP-1 Receptor Agonists Market Reactions Research and Development Sanofi Bristol Myers and Pfizer Regulatory Challenges Market Regulation Lobbying Patient Information Bayer Corporate Responsibility Discount Programs Compliance Lilly Noro Nordisk Collusion Price Increases Pfizer Inc. Product Quality Market Access IVF Drugs Merck KGaA EMD Serono Novo Nordisk Inc. Market Pricing Negotiation Practices Price Agreements Cost Reduction Strategies Rebate Plans Revenue Impact Price Negotiation Lawsuits Negotiation Processes Profitability Market History Opioid Distributors Legal Settlements Rebates PhRMA Distribution Companies Weight Loss Drugs Negotiation Process Market Trends Reformulation GSK Weight-loss Drugs Johnson & Johnson CEOs Bristol Myers Squibb

Trump Touts 'Affordability President' Rebrand, Claims Drug Prices Fell 500%–700%

Fact-checkers say the 500%–700% figures lack evidence, with confirmed drug‑price cuts to date limited to specific products and programs.

Medicare Sets 2027 Prices for 15 High-Cost Drugs, Including Ozempic

Judge Approves Revised Purdue–Sackler Opioid Settlement Requiring Up To $7 Billion

White House Clinches GLP-1 Price Deal as Lilly Sets Zepbound and Pill Pricing

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

U.S. Strikes Price-Cut Deals With Novo Nordisk and Eli Lilly for GLP‑1s, With Medicare Pilot in 2026

White House Seals Deals With Lilly and Novo to Cut GLP-1 Costs, Pilot Medicare Coverage

RFK Jr. To Announce New HHS Plan To Cut U.S. Drug Prices Today

AstraZeneca Strikes White House Drug-Price Deal, Wins Three-Year Tariff Reprieve

Colorado Sets First State Drug Price Cap, Limits Enbrel to $600 Per 50 mg Dose

White House Pauses Drug Tariffs as Pfizer Signs On to TrumpRx and MFN Pricing

AHA Seeks Antitrust Probe of Drugmakers’ 340B Rebate Plans

Trump Gives Pharma CEOs 60 Days to Adopt Most-Favored-Nation Drug Pricing

HHS Opens Applications for 340B Rebate Model Pilot

Bristol Myers Squibb and Pfizer to Offer Eliquis at 40% Cash-Price Discount